Results 51 to 60 of about 2,146 (159)

Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary

Journal of Comparative Effectiveness Research
What is this summary about? Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease where red blood cells break apart because they lack certain protective proteins.
Celso Arrais, Natalia Carnelutto, Jheremy Reyes   +2 more
doaj   +1 more source

Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta‐Analysis, and Meta‐Regression

European Journal of Neurology, Volume 33, Issue 8, August 2026.
Across 18 randomized trials involving 1823 participants, active therapies improved both QMG and MG‐ADL outcomes versus control. Trial‐level meta‐regression showed that each 10‐year increase in mean baseline age was associated with a 1.21‐point smaller QMG benefit, explaining 25.4% of between‐trial heterogeneity; the association appeared strongest in ...
Christopher Nelke, Marion Skrobol, Lukas Theissen, Francesco Sacca, Tobias Ruck   +4 more
wiley   +1 more source

Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD

Annals of Clinical and Translational Neurology, Volume 13, Issue 7, Page 1488-1492, July 2026.
ABSTRACT Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%–10.6 ...
Sean J. Pittock, Jin Nakahara, Becky Parks, Kerstin Allen, Sami Fam   +4 more
wiley   +1 more source

Diagnostic Challenges and Clinical Management of Area Postrema Syndrome: A Case Report on Persistent Nausea and Vomiting

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Area postrema syndrome (APS) is a rare neurological syndrome that presents a significant diagnostic challenge due to its nonspecific clinical manifestations, most commonly persistent nausea and vomiting, which frequently lead to initial misdiagnosis as a gastrointestinal disorder.
Andreea‐Gabriela Manole, D. Ion, Alexandra Bolocan, O. Andronic, D. N. Păduraru   +4 more
wiley   +1 more source

Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications.

PLoS ONE
IntroductionComplement component 5 inhibitor therapies (C5ITs) for rare hematological, renal, and neurological diseases are associated with increased meningococcal infection risk. Robust risk mitigation measures include vaccination, drug safety programs,
Cynthia Carrillo Infante, Arshad Mujeebuddin   +1 more
doaj   +1 more source

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers, Emmy J. Buter, Richard B. Pouw   +2 more
wiley   +1 more source

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety

HemaSphere, Volume 10, Issue 7, July 2026.
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra‐orphan disease. In 2026, approved complement inhibitors (CIs) for PNH include three C5 inhibitors (C5i) and three proximal inhibitors (PIs). Clinical trials for the approved PI pegcetacoplan, iptacopan, and C5i + danicopan had clear protocols for changing from terminal to PI, extrapolated ...
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, Jun‐ichi Nishimura, Christopher J. Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj   +15 more
wiley   +1 more source

Ravulizumab and Efgartigimod in Myasthenia Gravis

Neurology Neuroimmunology & Neuroinflammation
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, Malina Behrens, Christian W. Keller, Luisa Klotz, Sophie Lehnerer, Maike Stein, Meret Herdick, Paolo Doksani, Lea M. Gerischer, Sarah Hoffmann, Konstantinos Lazaridis, John Tzartos, Heinz Wiendl, Andreas Meisel, Jan D. Lünemann   +16 more
openaire   +4 more sources

Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder

Neurology and Therapy
Introduction Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversible and ...
Stacey L. Clardy, Sean J. Pittock, Orhan Aktas, Jin Nakahara, Noriko Isobe, Diego Centonze, Sami Fam, Adrian Kielhorn, Jeffrey C. Yu, Jeroen Jansen, Ina Zhang   +10 more
doaj   +1 more source

Ravulizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources